Turnstone rakes in $11.3 mln in Versant-led Series A funding
Turnstone Biologics Inc, a Toronto-based biotechnology company focused on developing novel oncolytic viral immunotherapies for cancer, has closed $11.3 million in Series A financing. U.S. venture capital firm Versant Ventures led the round, with participation from existing investor FACIT, a trust established by the Ontario Institute for Cancer Research. With the funding round, Turnstone named Dr. Sammy J. Farah as CEO and Dr. Brian D. Lichty as CTO, while adding Versant Partner Dr. Jerel Davis and Managing Director Dr. Brad Bolzon to its board of directors. The company said it will use the new investment's proceeds to expand development of its product portfolio.
28 October 2015•4 mins read
